Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2022-09-29 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT CONDITIONAL MARKETING APPROVAL OBTAINED IN CHINA FOR PUYOUHENG (PUCOTENLIMAB INJECTION) FOR THE TREATMENT OF INOPERABLE OR METASTATIC MELANOMA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Lepu Biopharma Co., Ltd. regarding the conditional marketing approval obtained in China for a drug (PUYOUHENG) for treatment of melanoma. It is an announcement of a regulatory approval event, describing the drug, clinical trial results, and impact on the company. There are no financial statements, no detailed financial performance data, no management discussion of financial results, no voting results, no director changes, no earnings data, no merger or acquisition information, and no regulatory certifications. The document is not a report but an announcement of a significant corporate event related to product approval. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement about a product approval and company update that does not fit other specific categories.
2022-09-29 English
VOLUNTARY ANNOUNCEMENT BREAKTHROUGH THERAPY DESIGNATION GRANTED BY THE CDE TO MRG003 FOR THE TREATMENT OF R/M NPC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Lepu Biopharma Co., Ltd. regarding the granting of breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for their drug candidate MRG003. The content focuses on regulatory and clinical development updates about the drug, its significance, and potential impact on the company. There are no financial statements, no detailed financial performance data, no meeting materials, no voting results, no executive changes, no earnings data, and no legal proceedings. The document is an announcement of a regulatory milestone and drug development progress rather than a formal report or filing. It is also relatively short (4879 characters) and does not contain or attach a full report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-29 English
2022 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT 2022' and contains detailed financial statements such as the 'INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS', 'BALANCE SHEET', 'STATEMENT OF CHANGES IN EQUITY', and 'STATEMENT OF CASH FLOWS'. It also includes a Management Discussion and Analysis section, corporate information, and notes on clinical trials and business operations. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of unaudited financial data for the half-year period ending June 30, 2022, confirms it is a comprehensive interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-09-27 English
(1) POLL RESULTS OF THE POSTPONED EGM AND POSTPONED CLASS MEETINGS HELD ON SEPTEMBER 23, 2022 AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURES FOR THE MEETING OF SHAREHOLDERS
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from a postponed Extraordinary General Meeting (EGM) and postponed class meetings of shareholders. It details the voting outcomes on various resolutions including share issuance, amendments to articles of association, and governance rules. The text explicitly states it is announcing the results of shareholder votes at these meetings. There is no substantive financial data or detailed report content; rather, it is a formal disclosure of voting outcomes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is substantial but the content is focused on voting results, not a full report or presentation. Therefore, the correct classification is DVA with high confidence.
2022-09-23 English
REVISED PROXY FORM FOR USE AT THE POSTPONED 2022 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a revised proxy form for a postponed 2022 first class meeting of domestic shareholders of Lepu Biopharma Co., Ltd. It contains detailed instructions for shareholders to appoint proxies and vote on various resolutions related to the issuance of A shares, authorization to the board, dividend plans, and amendments to articles. The content is focused on soliciting shareholder votes and providing voting instructions rather than reporting financial results or management commentary. This type of document is used to provide information and request votes from shareholders for a meeting, which fits the definition of a Proxy Solicitation & Information Statement (PSI). It is not an annual report, earnings release, or any other financial report, nor is it a simple announcement or certification. Therefore, the correct classification is PSI.
2022-09-08 English
REVISED PROXY FORM FOR USE AT THE POSTPONED 2022 FIRST CLASS MEETING OF H SHAREHOLDERS
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a revised proxy form for a postponed 2022 first class meeting of H shareholders of Lepu Biopharma Co., Ltd. It contains detailed instructions for appointing a proxy to vote on various special resolutions related to the issuance of A shares, authorization to the board, dividend plans, amendments to articles, and related party transactions. The content is focused on soliciting shareholder votes for specific resolutions at a shareholder meeting. This type of document is not a report, financial statement, or earnings release, but rather a solicitation and information statement for shareholders to vote at a meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length and detail confirm it is not a brief announcement or a simple voting result declaration, but a full proxy form for voting purposes.
2022-09-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.